Preventing kidney and heart damage in type 2 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary clinical trials.
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes (not type 1 or another rare type).
- Your diabetes lab test (HbA1c) was at least 6% within the last 12 months.
- You’re in a “secondary prevention” group (about 70% of participants) with age 40–80 and known blood-vessel disease from the heart, brain, or legs; or you fit the smaller “primary prevention” group (age 60–80 plus high-risk features).
- Your kidney function is not too low (eGFR must be 45 or higher for enrollment).
- You can take part in the random assignment of medication type (SGLT2 tablet/therapy and/or GLP-1 injection/therapy) through your usual pharmacy plan.
- You agree to use your medical record data and sign a release to get records from other doctors if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
This study looks at whether certain diabetes medicines, called SGLT2 inhibitors and GLP-1 receptor agonists, can help protect the heart in people with type 2 diabetes. It may help you understand if these treatments are a good option for your heart health.
This study compares different diabetes medicines to see which works best for people with type 2 diabetes who also have heart or blood vessel risks. It aims to find better treatment to protect your heart and kidneys.
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This trial tests a screening and intervention approach for “silent” coronary artery disease (heart artery narrowing without major symptoms) in people with type 2 diabetes. It may help prevent future heart problems by finding higher-risk cases early and starting the right treatment plan.
Hear when a new Type2diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.